# Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes

> **NCT01456130** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 67 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin
- **DRUG:** Rapid-acting insulin secretagogue

## Key facts

- **NCT ID:** NCT01456130
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01456130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01456130, "Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01456130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*